Efficacy and tolerability of bilateral sustained-release @entity619 intravitreal implants for the treatment of noninfectious posterior @entity1596 and macular @entity4 secondary to XXXX .

@entity1 @entity32 @entity9170 @entity231 @entity2994 @entity4 @entity1596 @entity619 @entity735 @entity941
PURPOSE: To report our experience with bilateral placement of @entity619 0.7 mg ( @entity9170 ) sustained-release intravitreal implant in the management of noninfectious posterior @entity1596 or macular @entity4 secondary to @entity2994 . METHODS: A retrospective chart review of @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 who were treated with @entity9170 intravitreal implant was performed. Ocular side effects such as intraocular pressure (IOP), @entity231 , and tolerability of bilateral injections was reviewed. RESULTS: Twenty-two eyes of eleven @entity1 treated with a total of 32 @entity9170 implants were included. Ten of eleven @entity1 received bilateral implants due to active noninfectious @entity1596 while the other demonstrated macular @entity4 in @entity735 following separate central @entity2994 . Among the @entity1 with bilateral @entity1596 , the mean interval between @entity9170 implant in the initial eye and the subsequent @entity9170 in the fellow eye was 15.6 days (range 2-71 days). Seven of the ten @entity1 received the second implant in the fellow eye within 8 days of the initial implantation. None of the @entity1 had bilateral implantations on the same day. Seven eyes required reimplantation for recurrence of @entity32 (mean interval between first and repeat implantation was 6.00  2.39 months). Following single or, in the case of the aforementioned seven eyes, repeat @entity9170 implantation, all 20 uveitic eyes demonstrated clinical and/or angiographic evidence of decreased @entity32 in the form of reduction in vitreous cells on slit lamp ophthalmoscopy, macular @entity4 on ophthalmoscopy, or optical coherence tomography and/or disc and vascular leakage on @entity941 angiography. The mean follow-up for all eyes after initial implantation was 23.57 months (range 1-48 months). IOP was significantly higher (P=0.028) at 6 months (16.62 mmHg   5.97) but not (P=0.82) at most recent follow-up (14.9  3.37 mmHg) when compared with baseline (14.68  3.02 mmHg). Four eyes (18.2%) required initiation of IOP-lowering medications. During the follow-up period, no eyes underwent filtration or @entity231 extraction. No serious ocular adverse effects were noted during the follow-up period. CONCLUSION: In @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 , bilateral injection of @entity9170 intravitreal implant was well tolerated and had an acceptable safety profile.
